These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure]. Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662 [TBL] [Abstract][Full Text] [Related]
5. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Stratta P; Canavese C; Quaglia M; Fenoglio R Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228 [No Abstract] [Full Text] [Related]
6. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media. Canga A; Kislikova M; Martínez-Gálvez M; Arias M; Fraga-Rivas P; Poyatos C; de Francisco AL Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056 [TBL] [Abstract][Full Text] [Related]
13. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Weinreb JC; Abu-Alfa AK J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035 [TBL] [Abstract][Full Text] [Related]
14. Is it safe to use gadolinium-based contrast agents in MRI? Pullicino R; Das K J R Coll Physicians Edinb; 2017 Sep; 47(3):243-246. PubMed ID: 29465099 [TBL] [Abstract][Full Text] [Related]
15. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis]. Varela CU; Prieto-Rayo JC Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439 [TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765 [TBL] [Abstract][Full Text] [Related]
17. Gadolinium and nephrogenic systemic fibrosis: association or causation. Kurtkoti J; Snow T; Hiremagalur B Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255 [TBL] [Abstract][Full Text] [Related]
18. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350 [TBL] [Abstract][Full Text] [Related]
19. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Abraham JL; Edward M AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307 [No Abstract] [Full Text] [Related]
20. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review. Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]